Genetic variants that inactivate protein-coding genes are a powerful source of information
about the phenotypic consequences of gene disruption: genes that are crucial for the function …

Genetic variants that inactivate protein-coding genes are a powerful source of information
about the phenotypic consequences of gene disruption: genes critical for an organism’s …

More than 100,000 genetic variants are reported to cause Mendelian disease in humans,
but the penetrance—the probability that a carrier of the purported disease-causing genotype …

Naturally occurring human genetic variants that are predicted to inactivate protein-coding
genes provide an in vivo model of human gene inactivation that complements knockout studies …

Lowering of prion protein (PrP) expression in the brain is a genetically validated therapeutic
hypothesis in prion disease. We recently showed that antisense oligonucleotide (ASO)-…

The cost of drug discovery and development is driven primarily by failure 1 , with only about
10% of clinical programmes eventually receiving approval 2 , 3 – 4 . We previously …

Prion disease is a fatal, incurable neurodegenerative disease of humans and other mammals
caused by conversion of cellular prion protein (PrP C) into a self-propagating neurotoxic …

In this Article, author Marquis P. Vawter was missing from the Genome Aggregation
Database Consortium list. They are associated with the affiliation:‘Department of Psychiatry & …

Prion disease is a rare, fatal, and exceptionally rapid neurodegenerative disease. Although
incurable, prion disease follows a clear pathogenic mechanism, in which a single gene gives …

Antisense oligonucleotides (ASOs) dosed into cerebrospinal fluid (CSF) distribute broadly
throughout the central nervous system (CNS). By modulating RNA, they hold the promise of …